Understanding the role of glioma-associated oligodendroglia in glioma progression

Pediatric low-grade gliomas (pLGGs) are the most common solid brain tumors in children and can lead to serious long-term health issues and even death. These tumors are often driven by genetic changes, particularly mutations in the BRAF gene, which can cause tumor cells to grow uncontrollably. Additionally, when other genetic changes co-occur with the BRAF mutation, the tumor may worsen and develop into a more aggressive high-grade form with a poorer prognosis.
To better understand how these tumors progress, we have created mouse models that mimic the progression of low-grade gliomas to high-grade gliomas. These models help study how tumors grow and how non-malignant cells in the surrounding environment influence tumor development. We found that non-malignant glioma-associated oligodendroglia undergo dynamic morphological and functional changes that could help promote tumor progression. While these mouse models are valuable in understanding the role of glioma-associated oligodendroglia, studying human data is crucial for more accurately predicting how these cells in the tumor behave and for finding better treatments targeting these cells.
The goal of this research is to complement existing animal models with human data to better understand the cellular and molecular changes in glioma-associated oligodendroglia that happen in gliomas as they progress. We hope that by comparing these findings with mouse studies, we can identify new ways to stop gliomas from becoming more aggressive and to improve existing treatments, especially those targeting the BRAF mutation.
The request for human data (single-cell RNA-seq and spatial transcriptomics) from the CBTN is vital for this work. By studying human tumor data, we will be able to identify key molecular markers that also exist in glioma-associated oligodendroglia and better understand the progression of gliomas in children, which will ultimately guide the development of more effective therapies. These insights can lead to the identification of novel treatment strategies that combine existing therapies with new targets, helping to prevent tumors from progressing into aggressive forms.
This research has the potential to greatly impact how pediatric gliomas are treated and could lead to better outcomes for children diagnosed with these devastating tumors.